HETLIOZ® receives EC approval for treatment of on-24-hour sleep-wake disorder
Vanda Pharmaceuticals announced the European Commission approved HETLIOZ® (tasimelteon) for treatment of Non-24-Hour Sleep-Wake Disorder in totally blind adults in the EU. The EC has also confirmed orphan drug designation for HETLIOZ®. July 06, 2015